TAK-700 8 antagonist intrathecally) dose-dependently prevents CFA-induced pain

intrathecally) dose-dependently prevents CFA-induced pain behavior and the associates SGK1 phosphorylation

105(1):136-144

Epub 2012 Dec 4

Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments

58 μM on HCT116 cells

TAK-700 8 antagonist intrathecally) dose-dependently prevents CFA-induced painTAK 700, is an orally bioavailable non steroidal androgen synthesis inhibitor of steroid 17alpha monooxygenase (17, 20 lyase) with potential antiandrogen activity. TAK 700 binds to and inhibits the steroid 17alpha monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen dependent growth signaling and may inhibit cell proliferation of androgen dependent tumor cells. Product information CAS